A research study on magic mushrooms in Canada found that nearly 80% of participants advocated for the medical use of psilocybin for patients under distress. Additionally, about two-thirds of the Canadian participants from the same study expressed their approval for psilocybin to be legally available for those in need.
Besides advocating for its availability, a substantial 84.8 percent of participants opined that the public health system should bear the costs of such therapies. A majority of Canadians see psilocybin as a feasible option, especially for treating end-of-life distress.
[toc]
Key Findings:
- Residents of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a valid medical option for managing end-of-life existential distress.
- Magic mushrooms are deemed safe for treating existential distress.
- Participants in two double-blind trials reported immediate and long-lasting benefits, with effects persisting for six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals face their mortality. They may encounter feelings of helplessness, isolation, anxiety, and a sense of lost meaning and purpose. This form of distress particularly impacts patients battling life-threatening illnesses and can even lead to thoughts of hastening death or contemplating suicide.
Generally, individuals grappling with terminal illnesses or substantial life changes are the ones most likely to suffer from this type of distress. It greatly impairs their mental well-being and overall life quality.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It may necessitate multiple sessions and may not be effective for all.
The unpredictability of such therapy’s effectiveness is a leading cause for individuals seeking alternative treatments.
Health Canada’s Standpoint on Psilocybin as a Therapeutic Solution
The last two decades have seen preliminary clinical trials emphasizing the possible advantages of psychedelic substances for managing complex mental disorders. Specifically, Psilocybin has demonstrated a quick and long-lasting reduction of existential distress in patients facing end-of-life care.
Recognizing the potential effectiveness of these proposed hallucinogenic mushrooms, especially when traditional therapies fail, Health Canada revised the Special Access Program in 2022. This revision enables healthcare practitioners to request controlled substances for their patients.
Canadian Advocacy for Psilocybin Access
A study published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, 19% of whom had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% see psilocybin-assisted therapy as a valid medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
The findings align with surveys conducted in Canada, England, and Australia. The researchers highlighted that their study is distinctive as it focuses on the use of psychoactive substances to relieve existential distress in end-of-life situations.
Why Canadians Support the Use of Psilocybin
An increasing number of Canadians are accepting the application of psilocybin for treatment, primarily due to evidence from esteemed research institutions. Another influential factor is the perceived safety of psilocybin mushrooms in easing existential distress. Participants in various studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients were given a high dose of psilocybin and a low dose as an active placebo control | Immediate and sustained |
| The treatment’s efficacy is largely due to mystical experiences marked by a profound sense of unity and deep emotional insights, which can provide benefits lasting up to six months or longer. | ||
| New York University Study | 29 patients were randomly chosen to either receive psilocybin or the active control substance, niacin. | The results were in line with the Johns Hopkins study. Those administered psilocybin reported psychological relief and a refreshed outlook on life and death. |
| BMC Palliative Care | Nineteen participants, including 7 doctors, 4 practicing nurses, 4 chaplains, 3 social workers, and a psychologist were interviewed. The study aimed to understand the perceptions of palliative care professionals on existential distress and their views on psychedelic therapy as a potential treatment. | As per the palliative care professionals, psychedelic-assisted therapy (PAT) exhibits promise in alleviating existential distress. |
Patient Experiences
Beyond scientific studies, numerous patient stories further attest to the effectiveness of psilocybin in promoting mental health and enhancing the quality of life.
Yokoi’s Experience
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, shares a transformative experience during her assisted therapy. She visualizes herself on a raft, surrounded by nature, and in the company of imaginary creatures. This vision imparts her with a profound sense of the universe’s unity and support, providing her with immense peace and affirmation.
Despite availing conventional mental health support, Yokoi continued to grapple with acute anxiety and distress post her diagnosis. Psilocybin therapy enabled her to reconnect with her body and bestowed a tangible sense of love and support. This significantly improved her emotional and mental wellbeing.
Chrissy’s Narrative
Chrissy, a woman in her 50s, was battling stage 4 breast cancer that had metastasized to her lungs. She was working full time as an administrative supervisor in healthcare at the time of the study and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her levels of anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any modifications in her religious or spiritual beliefs post her therapy session, she stated that the experiences had infused her beliefs with meaning and substance.
Brenda’s Journey
In the course of her therapy sessions, Brenda underwent two near-death experiences. She emerged from these sessions with no fear of death, seeing it as a natural part of life’s journey. She recognized her participation in the study as the catalyst for healing from her childhood trauma. The data collected during the study reflected her remarkable transformation.
The study noted a reduction in her anxiety and fear of death, along with an increase in her sense of spirituality.
Availability of Magic Mushroom Products in Canada
At present, the distribution of psilocybin capsules and similar products designed to manage existential anxiety or other mental health conditions may be limited. Nevertheless, reliable online dispensaries can serve as an excellent source for these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some surrounding South American countries. | Discovered in Cambodia, particularly around the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which gained recognition in the 1970s. |
| Potency | Moderately potent; suitable for first-timers. | Moderately potent as well; perfect for beginners. | Extremely potent; advised for those with moderate to advanced experience. |
| Effects | Causes a mental buzz, slight confusion, enhanced color awareness, euphoria, spiritual encounters, increased creativity, and improved concentration. | Triggers an energizing and long-lasting high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal visuals, and feelings of joy. | Induces profound shamanic experiences, vision quests, intense mystical experiences, enhanced creativity, focus, social consciousness, and mood improvement. |
Using Psilocybin Products to Ease End-of-life Discomfort
Existential or end-of-life distress can put a heavy burden on many patients nearing the end of their lives. Conventional treatments for this distress can sometimes be inadequate, leading to a surge in Canadian advocacy for easier public healthcare access to magic mushrooms. This growing public interest could We urge governing bodies to consider the potential of magic mushrooms as an effective treatment option. Obtain your psychedelics and mushroom deliveries from Magic Mushrooms Online Canada.
Frequently Asked Questions
What should patients expect when undertaking Psilocybin-Assisted Therapy?
The patient experience in Psychedelic-assisted therapy (PAT) can differ widely, making thorough preparation and adherence to specific procedures crucial for a positive outcome. Patients must complete extensive screening and mental readiness steps before ingesting the substance.
- Prior to the Session: Patients undergo a detailed assessment. The therapist establishes the patient’s goals and expectations, setting the intentions for the session. The therapist will also explain the potential effects of the process and what the patient can expect during the session.
- The Session Itself: During the session, patients receive a regulated dose of the substance in a peaceful, distraction-free environment conducive to relaxation and self-reflection. The therapist remains available for constant support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy helps patients comprehend and assimilate their experiences. Follow-up sessions continue to offer support and counselling, reinforcing the insights and changes achieved during the therapy.
How does psilocybin affect the brains of patients experiencing distress?
Psilocybin interacts with the brain by attaching to serotonin receptors, particularly the 5-HT2A receptor. This interaction can cause changes in perception, mood, and cognition, leading to profound alterations in consciousness, emotional breakthroughs, and new insights.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients with specific mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Readings:
